Stoke Therapeutics (STOK) Q2 2026 Earnings Call Transcript

Stoke Therapeutics reported Phase III EMPEROR enrollment completion at 162 patients, with 145 patients through week 8 and 60 patients through the week 28 primary endpoint timepoint, alongside 0% discontinuations to date (vs. 15% assumed). Management guided a rolling NDA initiation in Q1 2027 (starting with CMC) and expects clinical data completion by Q3 2027, targeting a potential early-2028 U.S. commercial launch. Financially, pro forma cash rose to ~$420M after an additional $65.7M ATM raise; Q2 revenue was $9.3M and net loss was $61.6M (~$0.93/sh), while R&D increased to $49.5M as zorevunersen advanced.

Analysis

STOK is no longer trading as a pure science option; the balance-sheet cleanup and lack of treatment attrition materially reduce the chance that the next 12 months are consumed by financing risk or protocol collapse. That matters because rare-disease biotech rerates fastest when investors can underwrite a commercial launch path before the pivotal readout, not after it. The likely beneficiaries are the company and, to a lesser extent, ex-U.S. partner economics; the losers are incumbent Dravet symptom managers whose usage may gradually erode once a disease-modifying standard becomes financeable and operationally real.

The key risk is regulatory, not clinical, over the next 1-3 months: if the agency narrows what can be filed or treats the long-duration dataset as supportive rather than label-shaping, the market will need to push out the “disease-modifying pricing” story. Over 6-18 months, the harder problem is commercial friction — a concentrated prescriber base helps, but intrathecal logistics, prior auth, and center throughput create a slow adoption curve that can cap near-term revenue multiple expansion even with a clean Phase III path. Falsifier: any hint of discontinuations, a materially less favorable FDA meeting, or evidence that the NDA package must wait for the 2027 readout to matter.

Contrarian view: consensus may be overweighting the importance of the next clinical update and underweighting the FDA pre-NDA meeting as the true rerating event. But consensus is also probably underestimating how much of the current valuation already embeds a fast 2028 launch, which is too aggressive for a CNS launch with site-level operational constraints. This is a gradual rerating setup, not a straight-line momentum trade.

Key Decisions for Investors

• Staged long STOK now, with half-size ahead of the fall pre-NDA meeting and add only if FDA alignment is explicit on rolling submission sequence and endpoint hierarchy; upside is a multi-quarter rerating, downside is a sharp de-rate if the agency constrains the label story.
• Pair long STOK / short XBI for 3-6 months to isolate idiosyncratic regulatory de-risking from broad biotech beta; this works best if the stock begins trading on execution milestones rather than market risk appetite.
• If STOK rallies hard into the pre-NDA meeting, monetize some upside via covered calls or a partial trim; the main binary remains the 2027 Phase III readout, so front-end upside should be treated as event-premium, not conviction.
• Use the next FDA communication as the thesis checkpoint: add only if the meeting supports a fileable package and long-term data inclusion; reduce or exit if the agency signals the OLE package is non-label-enabling.
• Watch for any need to re-finance before launch; if burn accelerates without regulatory clarity, fade strength rather than chase the equity.